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Abstract: This study explores the longitudinal relationship between
patient characteristics and use of 4 drug classes (antihypertensives,
antidepressants, antipsychotics, and hormones) that showed
significant changes in use rates over time in patients with Alzheimer
disease. Patient/caregiver-reported prescription medication usage
was categorized by drug class for 201 patients from the Predictors
Study. Patient characteristics included use of cholinesterase
inhibitors and/or memantine, function, cognition, living situation,
baseline age, and sex. Assessment interval, year of study entry, and
site were controlled for. Before adjusting for covariates, useage
increased for antihypertensives (47.8% to 62.2%), antipsychotics
(3.5% to 27.0%), and antidepressants (32.3% to 40.5%); use of
hormones decreased (19.4% to 5.4%). After controlling for patient
characteristics, effects of time on the use of antidepressants were no
longer significant. Antihypertensive use was associated with poorer
functioning, concurrent use of memantine, and older age.
Antipsychotic use was associated with poorer functioning and
poorer cognition. Antidepressant use was associated with younger
age, poorer functioning, and concurrent use of cholinesterase
inhibitors and memantine. Hormone use was associated with being
female and younger age. Findings suggest accurate modeling of the
Alzheimer disease treatment paradigm for certain subgroups of
patients should include antihypertensives and antipsychotics in
addition to cholinesterase inhibitors and memantine.
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Pharmacy costs account for nearly one-third of costs formedicare beneficiaries with Alzheimer disease (AD),1
and these costs are persistent from year to year.2 However,
there is little literature documenting patterns of prescription
medication use among patients with AD.
In an earlier report, we examined patterns of
cholinesterase inhibitors and memantine use over time in
a large cohort of patients with AD enrolled in the
Predictors Study at 3 US academic AD centers.3 In this
follow-up study, we aim to expand our understanding of
resource utilization in AD as applied to other pharmaceu-
tical interventions. We examined (1) patterns of utilization
in 4 drug classes (ie, antihypertensives, antidepressants,
antipsychotics, and hormones) that showed significant
changes in use rates in our 6-year study period and (2)
the longitudinal relationships between patient character-
istics and drug use. Our study design allows for substan-
tially longer term analysis than can generally be conducted
in clinical trials. Clinical information included in the
Predictors Study also allows for more detailed examination
of the relationship between medication use and patient
characteristics than would be possible with insurance claims
data. As the prevalence rates of AD continue to rise,
understanding patterns of medication use will help inform
appropriate policy and care decisions.
METHODS
Sample
The sample was drawn from the Predictors 2 cohort,
consisting of patients recruited from Columbia University
Medical Center, Johns Hopkins School of Medicine, and
Massachusetts General Hospital. The study was approved
by each local institutional review board. The inclusion/
exclusion criteria are fully described elsewhere.4,5 Briefly,
subjects met Diagnostic and Statistical Manual of Mental
Disorders-III-R criteria for primary degenerative demen-
tia of the Alzheimer type and National Institute of
Neurological and Communication Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria for probable AD. Enrollment
required a modified Mini-Mental State Examination score
Z30, equivalent to approximately Z16 on the Folstein
Mini-Mental State Examination (MMSE).6,7 ClinicalCopyright r 2010 by Lippincott Williams & Wilkins
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diagnosis of AD has been confirmed in 93% of those
patients with postmortem evaluation.8 Patient recruitment
began in 1997. After the baseline interview, patients were
followed annually. Study recruitment was staggered: 3.0%
(n=6) entered the study in 1997, 8.5% (n=17) in 1998,
8.0% (n=16) in 1999, 26.9% (n=54) in 2000, 24.4%
(n=49) in 2001, 13.4% (n=27) in 2002, 10.0% (n=20) in
2003, and 6.0% (n=12) in 2004 or later. For data used in
this analysis, 17 patients had one assessment (8.5%), 41 had
2 (20.4%), 32 had 3 (15.9%), 36 had 4 (17.9%), 33 had 5
(16.4%), and 42 had 6 or more assessments (20.9%).
Median follow-up for the cohort was 4 years. Patients who
did not respond at a particular visit could respond at a
subsequent visit. The analysis sample consisted of 785
observations from 201 patients.
Measures
Medication Use
Detailed descriptions of both prescription and over-
the-counter medications were reported by patients and infor-
mants. A neurologist who specializes in dementia (N.S.)
categorized all 429 unique prescription medications reported
in the data into the following 18 categories: anticoagulants,
antiplatelets, nonsteroidal anti-inflammatory drugs, antihis-
tamines, prostate anticholinergic, antihyperlipidemics, anti-
diabetics, antihypertensives, antiepileptics, antipsychotics,
antiemetics, neuroleptics, stimulants, antiparkinsonians, anti-
depressants, benzodiazepines, narcotics, hormones, and other
prescription medications. A complete list of medications
by category is available upon request from the authors. For
each drug category, we constructed a dichotomous variable
indicating whether a patient reported using any medications
in that category since the last visit. We focused on drug
classes instead of individual drugs because access to specific
drugs may vary depending on insurance coverage and
physician preference. Because an earlier analysis showed
significant changes in use rates over time in 4 of the 18 drug
classes (ie, antihypertensives, antidepressants, antipsychotics,
and hormones) and stable or low frequency of use in the
other 14 drug classes,3 we focus on these 4 drug classes in this
study.
Patient Clinical and Demographic Characteristics
Data on clinical characteristics of the patients were
recorded at each visit. Disease progression was character-
ized by transition from milder stages of dementia to more
severe stages, measured by MMSE.6 Higher MMSE scores
indicate better cognition. Blessed Dementia Rating Scale
(BDRS) Parts I (Instrumental Activities of Daily Living)
and II (Basic Activities of Daily Living) were used to assess
patients’ functional capacity.9 Higher BDRS scores indicate
worse functioning. At baseline, demographic characteristics
(eg, age, ethnicity, sex, and education) were recorded.
Information on living arrangements was collected at each
visit, dichotomized as living at home or in a long-term
care facility (ie, retirement home, assisted living facility, or
nursing home).
Analysis
We used random effects logistic regression models to
examine the effects of patient characteristics on utilization
rates of antihypertensives, antidepressants, antipsychotics,
and hormones over time. The random effects logistic
regression framework allows an exploration of the combi-
nation of fixed effects that are common to all individuals in
the population or common to groups of individuals and
random effects that indicate individual level variations. The
fixed effects parameters are interpreted as average effects of
each explanatory variable on the dependent variables. The
random effects parameters are interpreted as deviations
from the mean for each individual and, therefore, model the
magnitude of unobserved heterogeneity.
In our estimation model, we included time as measured
in years following baseline (year 0). The coefficient on year
estimates average linear trend in the dependent variable over
time. An odds ratio (OR) greater than 1 on the coefficient
on time indicates increasing likelihood of use over time. We
included a year squared term in the model to estimate
whether the rate of change over time was constant. The year
squared term was not statistically significant in any of the
models, and, therefore, was dropped.
All clinical variables and living arrangement were
entered in our estimation model as time-variant covariates.
Age at baseline and sex were entered as time-invariant
covariates. Because the sample was overwhelmingly white
(93%), we did not include race as an explanatory variable.
In addition, we controlled for concurrent use of cholines-
terase inhibitors and memantine and year of study entry
in the regression models. We also controlled for possible
differences in use patterns by region by including study site
as a covariate. Because patients’ psychiatric symptoms and
extrapyramidal signs did not significantly affect use of any
of the drug classes we examined here, we excluded these
variables from our final models. All analyses were per-
formed using Stata 9.0.10
RESULTS
Patient Characteristics
At baseline, patients’ average age was 76 years
(SD=8.1), 61% were female, 93% were White, and 84%
lived at home (Table 1). Patients were well educated, with
an average of 14 years of schooling (SD=3.1). Average
MMSE was 22.0 (SD=3.5) and average BDRS was 4.8
(SD=2.5). Psychotic symptoms (34%) and extrapyramidal




Baseline age 76.3 (8.1)
Live at home (%) 84.0
Functional capacity, BDRS 4.8 (2.5)
Folstein MMSE 22.0 (3.5)
Extrapyramidal signs (%) 15.5
Psychotic symptoms (%) 33.8





Year of entry into study 2001 (1.9)
BDRS indicates Blessed Dementia Rating Scale; MMSE, Mini-Mental
State Examination.
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signs (16%) were common. On average, patients had 1.5
comorbidities (SD=1.1), with 15% with none, 43% with 1,
26% with 2, and 16% with 3 or more comorbidities.
The most prevalent comorbidities at baseline were hyper-
tension (35.5%), diabetes (10.7%), myocardial infarction
(6.6%), congestive heart failure (4.6%), and chronic
obstructive pulmonary disease (4.6%).
Figure 1 shows changes in utilization rates of anti-
hypertensives, antidepressants, antipsychotics, and hor-
mones during the study period. Tests for trend over time
showed significant increases in utilization rates of anti-
hypertensives (47.8% to 62.2%), antidepressants (32.3% to
40.5%), and antipsychotics (3.5% to 27.0%), and decreases
in hormone use (19.4% to 5.4%; all P values for trend over
time <0.001).
Multivariate Results on the Relationship
Between Patient Characteristics
and Medication Use
We used random effects logistic regression models to
examine the relationships between patient characteristics
and utilization of antihypertensives, antidepressants, anti-
psychotics, and hormones. After controlling for patient
demographic and clinical characteristics, use of anti-
hypertensives (OR=1.217, P<0.05) and antipsychotics
increased (OR=1.883, P<0.001), use of hormones de-
creased (OR=0.636, P<0.01), and the effects of time on
use of antidepressants were no longer significant (Table 2).
For both antihypertensives and antipsychotics, the rate of
increase in utilization slowed over time (OR=0.984 and
0.963, respectively, both P<0.05).
After controlling for time and other covariates, different
demographic and clinical characteristics were associated
with use of different medication classes. Specifically, poorer
functioning (OR=1.229, P<0.01), concurrent use of mem-
antine (OR=2.725, P<0.05), and older age (OR=1.061,
P<0.05) were associated with higher likelihood of anti-
hypertensive use. Younger age (OR=0.922, P<0.05), poorer
functioning (OR=1.432, P<0.001), and concurrent use of
cholinesterase inhibitors (OR=2.417, P<0.05) and meman-
tine (OR=2.483, P<0.05) were associated with higher like-
lihood of antidepressant use. Poorer functioning (OR=1.328,
P<0.01) and poorer cognition (OR=0.835, P<0.001)
were associated with higher likelihood of antipsychotic use.

















FIGURE 1. Utilization rates of antihypertensives, antidepressants,
antipsychotics, and hormone over time, indicates anti-
depressants; , antihypertensives; antipsychotics,
, hormones.









Interval 1.217 (0.163)* 1.062 (0.145) 1.883 (0.448)*** 0.636 (0.115)**
Interval squared 0.984 (0.012)* 0.997 (0.013) 0.963 (0.020)* 1.025 (0.019)
Functional capacity, BDRS 1.229 (0.103)** 1.432 (0.124)*** 1.328 (0.162)** 1.036 (0.112)
Cognition, Folstein MMSE 1.056 (0.039) 1.027 (0.037) 0.835 (0.042)*** 0.973 (0.045)
Concurrent use of cholinesterase inhibitors 1.294 (0.628) 2.417 (1.256)* 1.285 (0.925) 0.870 (0.524)
Concurrent use of memantine 2.725 (1.501)* 2.483 (1.361)* 0.915 (0.688) 0.737 (0.597)
Baseline age 1.061 (0.039)* 0.922 (0.033)** 0.963 (0.042) 0.902 (0.037)**
Female 0.846 (0.494) 1.203 (0.684) 1.958 (1.402) 7.280 (5.010)***
Live at home 0.440 (0.245) 0.812 (0.463) 0.314 (0.237) 0.798 (0.540)
Sitew
Johns Hopkins 0.394 (0.286) 2.261 (1.583) 1.088 (0.943) 4.767 (3.837)*
Massachusetts general 0.818 (0.562) 1.936 (1.304) 0.216 (0.183)* 2.570 (1.994)
Year of entry into study 0.984 (0.160) 0.876 (0.139) 0.877 (0.188) 0.957 (0.176)
AIC 625.67 606.39 305.27 372.58
BIC 687.60 668.31 367.20 434.50





AIC indicates akaike information criterion; BIC, Bayesian information criterion; BDRS, Blessed Dementia Rating Scale; MMSE, Mini-Mental Status
Examination; OR, odds ratios.
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(OR=0.902, P<0.01) were associated with higher likelihood
of hormone use.
DISCUSSION
The purpose of this study was to examine the patterns
of medication usage in a cohort of patients with AD and
provide information on the clinical and demographic
characteristics of patients that are associated with use of
specific classes of drugs. We found that after controlling for
demographic and clinical characteristics, use of antihyper-
tensives and antipsychotics increased, whereas use of
hormones decreased over time. Use of antidepressants also
increased over time, but the trend over time was no longer
significant after controlling for patient characteristics.
These findings suggest that pharmacological treatment for
AD changes with disease duration, and may include
antihypertensives and antipsychotics, in addition to the
use of cholinesterase inhibitors and memantine.
The increasing rates of antihypertensive use over time
may be related to several factors. Rates of hypertension
increase with increasing age.11,12 In this study, baseline
age was predictive of antihypertensive use. In a sensitivity
analysis, we additionally controlled for number of comor-
bidities, measured by the Charlson Comorbidity Index.
As expected, number of comorbidities was associated with
increasing antihypertensive use, but did not substantively
affect coefficient estimates. There is some evidence that
hypertension may be a risk factor for dementia,13 but the
effect of antihypertensive treatment on cognition is
ambiguous.13–15 In this study, there was no association
between cognition and antihypertensive use. Rather, lower
functional ability and memantine use were associated with
antihypertensive use, suggesting higher utilization in more
clinically severe patients.
Use of antipsychotics significantly increased over time
in this cohort, and was associated with worse cognition and
functioning, suggesting that antipsychotics are more likely
to be used in clinically severe patients. Antipsychotics may
be prescribed for various reasons, including hallucination,
delusion, aggression, agitation, irritability, wandering, poor
sleep, or occasionally depressive symptoms.16 However,
our results did not show an association between psychotic
symptoms and antipsychotic use, suggesting that patients
may have responded to the medications.
The finding of worse cognition and functioning being
associated with higher likelihood of antipsychotic use is in
accordance with previous findings from the Predictors
Study that both delusions and hallucinations17 and
disruptive behavioral symptoms18 were associated with
increased risk for cognitive and functional decline. Further
analyses may help elucidate if use of antipsychotics in this
cohort is related to other disruptive behavioral symptoms
that are common in AD, including agitation, aggression,
disinhibition, irritability, and wandering.19 Alternatively,
the association between antipsychotic use and worse
cognition and functioning may be due to antipsychotics
exacerbating cognitive and functional impairments. Of
note, data from the Predictors Study were collected before
the US Food and Drug Administration public health
advisory against the use of antipsychotics in elderly
dementia patients owing to increased risks for stroke and
overall mortality.20–22
Although unadjusted trends show increasing use of
antidepressants over time, this trend disappeared after
controlling for patients’ characteristics. An earlier study
using the Predictors data showed that depression in AD
patients neither increased nor persisted over time.23
Another study investigating the course of depression in
these patients reported that the prevalence of depression
was stable (B40%) during the first 3 years and significantly
decreased during the fourth (28%) and fifth (24%) years of
follow up.24 A lack of significant increases of antidepressant
use over time seems to follow the course of depressive
symptoms previously described in this cohort. Several
patient and clinical factors were associated with anti-
depressant use, including younger age, poorer functioning,
and cholinesterase inhibitors and memantine use. Consis-
tent with previous reports of decline in functioning, but not
in cognition preceding the first episode of depressive
symptoms in patients with probable AD,24 the association
between poorer functional status and more antidepressant
use found in our analysis may also reflect an effect of
depressive mood on functional skills.
As expected, hormone use was more common in
females (27.6% among females compared with 6.4%
among males at baseline). Although early observational
studies suggested that postmenopausal hormone treatment
may improve cognitive function, more recent data indicate
a lack of protective effect and possibly even a detrimental
effect for primary prevention.25–27 Similarly, effects of
hormone replacement therapy in course and prognosis
after AD onset have been equally disappointing.28 Decreas-
ing hormone use may reflect increased awareness of such
lack of efficacy of hormone therapy. Despite adjusting
for year of study entry and intervals, residual confounding
effects may still remain.
In this study, we provide a detailed examination of
utilization of different classes of prescription medications.
Because medication use was reported for 6-month intervals,
we were unable to account for medication changes in <6
months. In addition, patients were selected from tertiary
care university hospitals and specialized AD centers and
represent a nonrandom sample of those affected by the
disease in the population. Patients in our sample also were
predominantly White and highly educated. Caution is
needed in generalizing the results of this study to patients
of other ethnicities, patients at lower education and income
levels, and to community AD patients. On the other hand,
because patients were selected from specialized AD centers,
careful clinical diagnosis of AD and evaluations permitted
more reliable and complete data and more accurate
coefficient estimates. All classes of medications were
evaluated in detail by experienced neurologists. Because
patients were recruited at early disease stages and followed
for long periods of time, analyses are not compressed in
time and the cohort describes the full range of progression.
Longer term effects are, therefore, more easily interpreted
and strengthen the confidence in our findings.
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